Acquisition by Prashant Kohli of 128770 shares of Acasti Pharma at 2.96 subject to Rule 16b-3
ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Slightly above 50% of Acasti Pharma's private investors are presently thinking to get in. The analysis of current outlook of investing in Acasti Pharma suggests that some traders are interested regarding Acasti Pharma's prospects. Acasti Pharma's investing sentiment can be driven by a variety of factors including economic data, Acasti Pharma's earnings reports, geopolitical events, and overall market trends.
Acasti |
Filed transaction by Acasti Pharma Director, Officer: Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Acasti Pharma Fundamental Analysis
We analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Acasti Pharma is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Acasti Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acasti Pharma stock to make a market-neutral strategy. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics with similar companies.
Peers
Acasti Pharma Related Equities
JAGX | Jaguar Animal | 29.29 | ||||
MBRX | Moleculin Biotech | 14.72 | ||||
ABVC | ABVC Biopharma | 10.64 | ||||
ADTX | Aditxt | 1.77 | ||||
TNXP | Tonix Pharmaceuticals | 1.10 | ||||
GOVX | GeoVax Labs | 0.82 | ||||
PULM | Pulmatrix | 0.84 | ||||
OCGN | Ocugen | 1.14 | ||||
AKTX | Akari Therapeutics | 2.00 | ||||
IBIO | Ibio | 3.01 | ||||
BPTH | Bio Path | 3.38 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |